Chemoimmunotherapy may not be dead yet in chronic lymphocytic leukemia, but fludarabine plus cyclophosphamide plus rituximab is potentially facing life support

Research output: Contribution to journalLetterOtherpeer-review

1 Citation (Scopus)
Original languageEnglish
Pages (from-to)4093-4094
Number of pages2
JournalJournal of Clinical Oncology
Volume35
Issue number36
DOIs
Publication statusPublished - 20 Dec 2017

Cite this